Jul 01,2022

FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy

Intuitive (Nasdaq:ISRG) announced that the FDA cleared an integration of imaging technology with the Ion robot-assisted bronchoscopy system. The integration covers a mobile cone-beam CT (CBCT) imaging technology, developed by Siemens Healthineers, called Cios Spin. The integration of Ion with Siemens’ imaging technology could improve the accuracy of biopsy procedures, aiding in the diagnosis of lung cancer, the company said, through the enhancement of a physician’s ability to provide minimally invasive lung biopsy with Ion and potentially give patients answer sooner.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
Jul 07,2022

RefleXion, Mirada ink licensing deal on personalized cancer treatment

RefleXion Medical announced today that it entered into a non-exclusive, worldwide licensing agreement with Mirada Medical. The agreement allows for the integration of Mirada’s RegEngine image registration algorithms into the RefleXion X1 treatment planning software, aligning patient anatomy between different imaging modalities or between radiotherapy treatments.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 12,2022

Effectiveness of psychoeducation intervention among women with gynecological cancer: a systematic review and meta-analysis of randomized controlled trials

Psychoeducation interventions have been suggested to improve sexual functioning and quality of life. The aim of this study was to examine the effects of the psychoeducation intervention on quality of life, sexual function, and psychological outcomes; and to identify the critical components of psychoeducation intervention for women with gynecological cancer. The results show that incorporating lecture-based, practical skills, discussion, and counseling through an online format and involving significant others are beneficial for improving the quality of life and sexual functioning among women with gynecological cancer.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 15,2022

Medtronic, ASGE to expand colon screening program for underserved communities

With support from Amazon Web Services’ (AWS) Health Equity Initiative, Medtronic and ASGE are expanding the Medtronic Health Equity Assistance Program for colon cancer screening in medically underserved communities across the U.S., increasing GI Genius units (provided as part of the program) from 50 to 133 systems placed at 62 facilities.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Jul 28,2022

A common infrastructure for real-world patient-reported symptoms: one size fits many

Researchers now advocate a broadly accessible, common infrastructure for patient-reported toxicities from all patients—in the so-called real-world—to facilitate enhanced collection of clinically meaningful and actionable data.

CLINICAL STUDY

#rwd

View Analyst & Ambassador Comments
Go to original news
Jul 14,2022

Florida Cancer Specialists & Research Institute Participating in Global Clinical Trial Analyzing Patient Responsiveness to Immunotherapy Treatment

Florida Cancer Specialists & Research Institute medical oncologist Ernest Bustinza-Linares, MD is serving as a Principal Investigator in a global clinical trial collaboration that will analyze the responsiveness of certain cancer patients to immunotherapy treatment. FCS is one of 35 clinical trial sites globally participating in the study hosted by OncoHost, a global leader in next-generation precision oncology. OncoHost’s first-of-its-kind precision diagnostic platform, PROphet®, will be used to analyze patient response and identify resistance to immunotherapy.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 22,2022

JITC Publishes OncoHost Study Identifying Predictive Proteomic Signature to Analyze Treatment Resistance in NSCLC Patients

OncoHost, a global company in next-generation precision oncology for improved personalized cancer therapy, announced a peer-reviewed article published in Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal. The study highlights the role of blood plasma proteomic profiling for assessing resistance in non-small cell lung cancer patients being treated with immune checkpoint inhibitors.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 28,2022

“SYNERGY-AI” Bringing Cancer Patients Together with Clinical Trials 

Massive Bio brings cancer patients together with clinical trials no matter where they live in the world and under which economic conditions with the SYNERGY-AI. With SYNERGY-AI mobile phone application, cancer patients enter their information and Massive Bio’s artificial intelligence algorithms match their data with the most appropriate treatment method and the nearest clinical research center.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 29,2022

Massive Bio competes with world-class arti...

Massive Bio is launching personalized clinical research matching technology to reach 100 thousand cancer patients. The company provides cancer patients with personalized services at the right time and scale by performing comprehensive molecular profiling through Next Generation Sequencing (NGS) testing. Using Massive Bio’s artificial intelligence algorithms, patients enter their cancer data, and Massive Bio’s algorithms quickly identify the best treatment among existing clinical studies.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Aug 11,2022

Cancer Support Community and Carevive Partner on Innovative Care Delivery Model

The Cancer Support Community (CSC) and Carevive are partnering to provide an innovative nursing and social work team-based care delivery model to health systems across the U.S. Using best-in-class technologies, they will monitor and manage the physical and psychosocial distress of patients and caregivers impacted by a cancer diagnosis in collaboration with cancer care teams. Built on the proven success of both CSC’s CancerSupportSource® (CSS) distress screening tool and Carevive’s PROmpt cancer care management® program, this partnership offers an effective proactive approach to cancer care navigation.

COLLABORATION PARTNERSHIP

#product & service

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY